XTLB

XTL BIOPHARMACEUTICALS LTD XTLB

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$20.7K total
RHUMBLINE ADVISERS
$17.0K+4.0%
GAMMA Investing LLC
$3.3K-64.2%
UBS Group AG
$341New
See all 3 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/XTLB

Earnings Per Share

13fpro.ai/company/XTLB

Loading ratio trend…

XTLB key financials by period

Reported revenue, net income and operating margin by fiscal year, from XTL BIOPHARMACEUTICALS LTD's annual filings on SEC EDGAR.

XTL BIOPHARMACEUTICALS LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$451.0K$-1.0M-171.8%
Source: XTLB filings on SEC EDGAR →

About XTL BIOPHARMACEUTICALS LTD (XTLB): stock profile, AI score and financials

XTL BIOPHARMACEUTICALS LTD (XTLB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. XTLB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of XTLB by reported 13-F value include RHUMBLINE ADVISERS, GAMMA Investing, UBS Group AG, based on the most recent SEC filings. XTLB trades on the Nasdaq exchange and files with the SEC under CIK 1023549. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XTLB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XTL BIOPHARMACEUTICALS LTD directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1023549 →